|
ZymoGenetics Stage: Spin-outs Date of Investment: 2000 Web Site : http://www.zymogenetics.com Stock Symbol : Nasdaq: ZGEN |
 |
ZymoGenetics, Inc., based in Seattle, WA, is a biopharmaceutical company focused on the development and commercialization of protein therapeutics. The Company launched its first drug on the US market in 2008, and has a strong pipeline of additional product candidates in development with meaningful commercial potential.
Warburg Pincus has been a significant investor in ZymoGenetics since 2000, when the firm led the spinout of Zymo from Novo Nordisk A/S, a major pharmaceutical company based in Denmark.
